单克隆抗体在儿童特应性皮炎中的应用；有效性和安全性
Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.
摘要(中文译文)
特应性皮炎（AD）可引起湿疹、皮肤干燥和瘙痒，是儿童中最常见的皮肤病之一。除局部外用糖皮质激素和大量使用润肤剂外，单克隆抗体近年来已被用于中重度病例的系统性治疗。本研究旨在综述当前关于单克隆抗体（mAbs）用于治疗儿童AD的文献。为开展文献叙述性综述，我们在PubMed和Google Scholar中以关键词（单克隆抗体或生物制剂）和（儿科或儿童）和（特应性皮炎或湿疹）进行检索。特应性皮炎的病理生理机制仍需更深入的理解。目前已知与AD病理生理相关的最主要因素包括丝聚蛋白基因突变以及Th1和Th2细胞调节异常。细胞因子，如IL-4、IL-13、IL-17、IL-22、IL-31和IL-33，是导致IgE抗体产生并引起皮肤屏障破坏的关键介质。单克隆抗体相较其他系统性治疗具有若干优势。其中，度普利尤单抗、曲罗芦单抗、奥马珠单抗、奈莫利珠单抗、来瑞组单抗和贝那利珠单抗已显示出良好结果。中重度AD常需要系统性免疫调节药物（单克隆抗体）作为补充治疗。度普利尤单抗已获FDA批准用于儿童AD。其他单克隆抗体在用于儿童之前仍需进一步临床试验。
Abstract
Atopic dermatitis (AD), which causes eczema, dryness, and itching, is one of the most prevalent skin diseases in children. Along with topical corticosteroids and the liberal application of emollients, monoclonal antibodies have recently been used for systemic treatment in moderate to severe cases. This study aims to review the current literature on the application of monoclonal antibodies (mAbs) in treating children with AD. To conduct a narrative review of the literature, we searched for the keywords (monoclonal antibodies OR biologics) AND (pediatric OR children) AND (atopic dermatitis OR eczema) in PubMed and Google Scholar. The pathophysiology of atopic dermatitis still requires better understanding (or, remains incompletely understood). The most well-known factors contributing to the pathophysiology of AD include filaggrin gene mutations and abnormalities in Th1 and Th2 cell regulation. Cytokines, such as IL-4, IL-13, IL-17, IL-22, IL-31, and IL-33, are crucial mediators that lead to IgE antibody production and result in skin barrier degradation. Monoclonal antibodies have several advantages over other systemic therapies. Among these, dupilumab, tralokinumab, omalizumab, nemolizumab, lebrikizumab, and benralizumab have shown favorable results. A systemic immunomodulatory medication (monoclonal antibodies) is frequently required for moderate to severe AD as supplementary treatment. Dupilumab has received FDA approval for pediatric AD. Further clinical trials are needed for other mAbs before they are used in children.
如何引用
AMA
Niloofar Masoumi, Taha Monadi, Zahra Aminzade, Afsaneh Soltani, Hesam Noqani, Seyed Ehsan Enderami. Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.. Current therapeutic research, clinical and experimental. 2026; doi:10.1016/j.curtheres.2026.100833.
APA
Niloofar Masoumi, Taha Monadi, Zahra Aminzade, Afsaneh Soltani, Hesam Noqani, Seyed Ehsan Enderami (2026). Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.. Current therapeutic research, clinical and experimental. https://doi.org/10.1016/j.curtheres.2026.100833
GB/T 7714
Niloofar Masoumi, Taha Monadi, Zahra Aminzade, Afsaneh Soltani, Hesam Noqani, Seyed Ehsan Enderami. Monoclonal Antibodies in Pediatric Atopic Dermatitis; Efficacy and Safety.[J]. Current therapeutic research, clinical and experimental, 2026 doi:10.1016/j.curtheres.2026.100833.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出